Clinical Trial Update: A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of KD019 in autosomal dominant polycystic kidney disease completed; safety, pharmacokinetics, and dose-escalation results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• KD019

Snippet

Sponsor: Kadmon, a Sanofi Company | Conditions: Polycystic Kidney, Autosomal Dominant | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-11-08